CARsgen Therapeutics is at the forefront of developing innovative CAR T-cell therapies aimed at treating various forms of cancer, including hematological malignancies and solid tumors. Their approach includes a robust pipeline of differentiated products, leveraging advanced technologies such as the THANK-uCAR® platform, which enhances the survival and proliferation of allogeneic CAR T cells by incorporating a CAR that targets NKG2A, a receptor on natural killer (NK) cells. This technology addresses the challenge of NK cell-mediated rejection, allowing for improved persistence of CAR T cells in the presence of host immune responses. Additionally, CARsgen's CycloCAR® technology enhances the efficacy of CAR T cells against solid tumors by co-expressing cytokine IL-7 and chemokine CCL21, which promote T-cell recruitment, survival, and proliferation, ultimately leading to superior therapeutic outcomes.

Another significant innovation from CARsgen is the LADAR® technology, which aims to tackle the challenge of targeting tumor-associated antigens that are also present in normal tissues. This system utilizes an artificial receptor to control the expression of therapeutic genes in response to specific antigens, thereby minimizing off-target effects. The LADAR® technology allows for precise activation of CAR T cells or other therapeutic mediators only in the presence of the target antigen, significantly reducing potential toxicities associated with traditional therapies. Through these advanced technologies, CARsgen Therapeutics is committed to making cancer curable by enhancing the effectiveness and safety of cell therapies for patients worldwide.

China

CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.

CARsgen Therapeutics

Company Details